Related Experiment Video
Updated: Aug 26, 2026

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection
Published on: January 31, 2020
A case-control study of gynecomastia in HIV-1-infected patients receiving HAART
Sibtain Rahim1, Olivia Ortiz, Melanie Maslow
1Division of Infectious Diseases, Department of Medicine, New York University School of Medicine, New York, USA.
Abstract:
Gynecomastia has been reported to occur in HIV-infected patients receiving HAART. A retrospective case-control study was conducted to determine risk factors associated with this condition. Two control patients were randomly chosen for each of 23 case patients identified. An efavirenz-containing regimen was strongly associated with the development of gynecomastia (odds ratio, 20; P < .001). Case patients were not more likely to have lipodystrophy, low testosterone levels, chronic infection with hepatitis B or C virus, or liver dysfunction compared with control patients. None of these factors altered the efavirenz-associated risk when analyzed by multiple logistic regression. Efavirenz appears to be strongly associated with gynecomastia in HIV-infected patients receiving HAART.
Related Concept Videos
Cryptococcal Meningitis
Retrovirus Life Cycles
Cirrhosis I: Introduction
